Drug intelligence / Profile preview

Spongioflex

Development stage
Preclinical
Lead developer
Deutsches Institut für Zell- und Gewebeersatz
Modality
Stem Cell Therapies → Cell Therapies, Other Cell Types → Cell Therapies, Adoptive Cell Transfer → Cell Therapies
Administration
Surgical Implantation
01

Overview

Spongioflex is a sterile, human-derived demineralized allogeneic cancellous bone scaffold developed and manufactured by the Deutsches Institut für Zell- und Gewebeersatz (DIZG). It is designed as a biological alternative to synthetic implants for the partial replacement of the meniscus and other non-bony structures like the glenoid. The scaffold is produced through a process of decalcification and demineralization, resulting in a porous, sponge-like matrix that is hard when dry but becomes soft and pliable upon hydration. This pliability allows for easy intraoperative shaping and suturing. Spongioflex acts as a "cell-instructive" biocompatible scaffold that facilitates the migration and ingrowth of host cells, such as meniscal and synovial cells, into the tissue defect. It retains endogenous growth factors that promote the formation of new fibrocartilage without undergoing ossification, thereby aiming to restore joint homeostasis and postpone or prevent the onset of osteoarthritis.

Brand names
Spongioflex
Other names
demineralized allogenic human cancellous bone

Beyond the preview

Go deeper on Spongioflex.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Spongioflex.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call